EDGAR·FLOW

CASTLE BIOSCIENCES INC — Form 10-Q

Filed July 30, 2026 · analyzed by the Periodic Agent
10-Q — Neutral significance 18/100
What the filing says
Castle Biosciences adopted a Non-Employee Director Compensation Policy effective May 28, 2026, establishing annual cash retainers (Board Service: $55,000; Chair: $50,000 additional; Committee service: $5,000–$20,000 depending on role) and equity grants (Initial Grant: $400,000 RSU; Annual Grant: $260,000 RSU, both valued and vested over defined schedules). The policy includes standard change-of-control acceleration and expense reimbursement provisions. No specific director count, total cost, or prior compensation structure is disclosed in the exhibits provided.
Why this rating

Routine director compensation policy adoption; no material change or cost disclosed relative to $576M market cap. Boilerplate governance document.

View original filing on SEC.gov ↗ CSTL · stock on Yahoo Finance ↗

See more from July 30, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.